NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Dynavax saw some gains on Monday, though there was no major catalyst to explain the small and modest pop. Earlier in the month shares had broken out over 10% when it was reported that the company's management is exploring strategic options for Heplisav-B, the company's hepatitis B vaccine. Shares of Exelixis had a big day of trading yesterday, with a close of over 17% after it was revealed that the FDA has granted Cabometyx priority review as a first treatment for patients with advanced kidney cancer.

RDI Initiates Coverage on:

Dynavax Technologies Corporation
https://rdinvesting.com/news/?ticker=DVAX

Exelixis, Inc.
https://rdinvesting.com/news/?ticker=EXEL

Dynavax Technologies Corporation's shares closed up 1.83% on nearly 4 million shares traded on Monday. There was no significant news yesterday from the company, but earlier in the month, a report revealed that Dynavax management is looking at different strategic options for its hepatitis B vaccine, Heplisav-B. This includes a licensing deal or an outright sale. Traders have been on their toes in anticipation because it was revealed also that Heplisav-B is expected to get a nod of approval from the FDA soon. RBC Capital reiterated an "outperform" rating on the stock recently with a price target of $28.

Access RDI's Dynavax Technologies Corporation Research Report at:
https://rdinvesting.com/news/?ticker=DVAX

Exelixis, Inc.'s shares closed up a little over 17% yesterday with a new high of $32.50 hit during intra-day trading. It was a stellar day for the stock with shares hitting a 17-year high on trading volume nearly eight times higher than usual. The California-based company's Cabometyx has achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma in a phase 3 study. The treatment was also granted priority review as a first treatment for patients with advanced kidney cancer by the FDA. The company plans to submit an application to the FDA in the first quarter of 2018. CELESTIAL is a randomized, double-blind, placebo-controlled study of cabozantinib in patients with advanced HCC conducted at more than 100 sites globally in 19 countries that are done by Exelixis and its partner Ipsen. Chief Medical Officer of Exelixis, Gisela Schwab, M.D., commented, "The acceptance of the sNDA filing with a Priority Review is an important regulatory milestone for CABOMETYX and for our mission to improve treatment outcomes for patients with cancer. We look forward to working with the FDA as they review the application in our effort to offer CABOMETYX to patients with previously untreated metastatic RCC who are in need of new treatment options.?

Access RDI's Exelixis, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EXEL

Our Actionable Research on Dynavax Technologies Corporation (NASDAQ: DVAX) and Exelixis, Inc. (NASDAQ: EXEL) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com